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Inﬂammation is the body’s way of defending itself against noxious stimuli and pathogens.
Under normal circumstances, the body is able to eliminate the insult and subsequently
promote the resolution of inﬂammation and the repair of damaged tissues.The concept of
homeostasis is one that not only requires a ﬁne balance between both pro-inﬂammatory
mediators and pro-resolving/anti-inﬂammatory mediators, but also that this balance occurs
in a time and space-speciﬁcmanner.This reviewexamines annexinA1, an anti-inﬂammatory
protein that, when used as an exogenous therapeutic, has been shown to be very effective
in limiting inﬂammation in a diverse range of experimental models, including myocardial
ischemia/reperfusion injury, arthritis, stroke, multiple sclerosis, and sepsis. Notably, this
glucocorticoid-inducible protein, along with another anti-inﬂammatory mediator, lipoxin A4,
is starting to help explain and shape our understanding of the resolution phase of inﬂam-
mation. In so doing, these molecules are carving the way for innovative drug discovery,
based on the stimulation of endogenous pro-resolving pathways.
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INTRODUCTION
Inﬂammation is essential for the body to maintain homeostasis
and recover from tissue injury or noxious stimuli. However, a key
step in the inﬂammatory response is the resolution phase. Overly
aggressive or prolonged inﬂammation, which fails to resolve, can
lead to tissue destruction (Serhan and Chiang, 2008). The reso-
lution of inﬂammation was once thought to be a passive process,
but is now deemed to be very much an active phenomenon, and
one that is tightly controlled by endogenous“pro-resolving”medi-
ators. Resolution is accepted as one of the four major outcomes
for acute inﬂammation, the others being progression to chronic
inﬂammation, scarring, and ﬁbrosis (Cotran et al., 1999; Kohli and
Levy, 2009).
Over the years, interest has focused on anti-inﬂammatory
mediators that have pro-resolving properties. In particu-
lar, endogenous anti-inﬂammatory molecules, such as the
glucocorticoid-regulated protein annexin A1 (AnxA1), have par-
ticular appeal for drug discovery programs, based on the con-
tention that drugs founded on endogenous anti-inﬂammatory
molecular pathways couldmimic their pro-resolution effects while
potentially having fewer side effects than existing therapeutic
agents.
This review will focus on AnxA1, its history, mechanism of
action and its role in both innate and adaptive immunity and how
this 37 kDa protein has potential in drug discovery.
THE HISTORY OF ANNEXIN A1
In the late 1970s, a new protein was discovered and character-
ized by its ability to quash eicosanoid generation by affecting
phospholipase A2 (PLA2) activity. The action on arachidonate
and eicosanoid release in vitro, e.g., the inhibition of PGE2 and
LTB4 release by monocytes and neutrophils (Parente et al., 1984)
was accompanied by an inhibitory effect in experimental mod-
els of inﬂammation in vivo (e.g., TXA4 release from perfused
guinea pig lungs; Cirino et al., 1987). Different names were pro-
posed for this new protein, the molecular weight of which ranged
from 15 to 40 kDa: macrocortin (because it was isolated from
peritoneal exudates from glucocorticoid-treated rats), renocortin
(released rat renal medulla cells; Russo-Marie and Duval, 1982),
or lipomodulin (released from isolated neutrophils; Hirata, 1981),
but it was decided that it should be termed lipocortin 1. It
was accepted that these three proteins were functionally identi-
cal and all active fragments of the same precursor, thus it was
agreed that a uniform name should be chosen: lipocortin (Di
Rosa et al., 1984). In 1986, lipocortin was cloned (Wallner et al.,
1986) and the sequence was termed lipocortin 1. Today, the name
AnxA1 has been agreed on as a more appropriate choice, due to
the ability of this protein to “annex” phospholipid membranes.
Following on from this, AnxA1 has been shown to mimic the anti-
inﬂammatory effect of glucocorticoids in number of in vitro and in
vivo studies (the gene encoding AnxA1 is located on chromosome
19q24).
Annexin A1 is a 37-kDa member of the annexin superfamily
of calcium- and phospholipid-binding proteins, of which there
are currently 13 members. It consists of 346 amino acids and is
made of four repeated sequences, which are arranged around a
core [which represents the large majority (≥80%) of the protein],
giving the protein a “doughnut” shape. At low Ca2+ concentra-
tions, the N-terminal domain is embedded within the pore, but
elevations in [Ca2+] (≥1 mM, e.g., as in plasma or other biological
ﬂuids) expose this region and may thereby inﬂuence the biological
activity of the protein (Rosengarth et al., 2001a,b). All members
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of the annexin superfamily comprise of a core domain made up
of four similar repeats (six repeats in the case of AnxA6), each
approximately 70 amino acids long. The N-terminal region of
each member of the annexin superfamily is unique and as such
represents its own ﬁngerprint, and confers biological activity. It
is, however, still unknown as to whether there is any close reg-
ulation among members of the annexin family. It is likely that
is the case, e.g., in the case of AnxA2, cells appear to require it
as a structural/scaffolding protein that stabilizes and/or regulates
the dynamics of certain membrane domains. Thus, it is probable
that AnxA2 shares its activity with other annexins (Rescher and
Gerke, 2004).
BIOLOGY OF AnxA1
Within peripheral blood cells, under resting conditions, AnxA1
is mainly expressed in subcellular granules of neutrophils,
eosinophils, and monocytes, with small amounts expressed in spe-
ciﬁc subsets of lymphocytes (Goulding et al., 1990; Morand et al.,
1995; Rescher and Gerke, 2004; Spurr et al., 2011). T cells and
mast cells express the protein, although B cells express it at low
levels, and platelets do not (Cirino et al., 1987; Morand et al., 1995;
Oliani et al., 2000; Rescher and Gerke, 2004). Cell differentiation
(such as monocytes maturing into macrophages) tends to be asso-
ciated with higher levels of expression of AnxA1, as demonstrated
in studies showing that levels of AnxA1 expression are lower in
monocytes relative to those in macrophages from the same donor
(Perretti and Flower, 1996).
AnxA1 is undetectable in plasma, but is found in many tissues,
including the lung, bone marrow, and intestine, at concentrations
<50 ng/ml, with the highest levels in seminal ﬂuid (150 μg/ml).
AnxA1 AND THE INNATE IMMUNE RESPONSE
THE ROLE OF AnxA1
Since its discovery, AnxA1 has been shown to be capable of modu-
lating a number of biological events, including both acute (Gavins
et al., 2003) and chronic (Goulding et al., 1998) inﬂammation,
ischemia/reperfusion injury (D’Amico et al., 2000; La et al., 2001;
Gavins et al., 2003), pain (Marchand et al., 2005), fever (Lim and
Pervaiz, 2007), intracellular vesicle trafﬁcking (Gerke et al., 2005),
arachidonic acid release (Croxtall et al., 2000), leukocytemigration
(Williams et al., 2010), and tissue growth and apoptosis (Petrella
et al., 2005; Scannell and Maderna, 2006). AnxA1 may also play
a role in the regeneration of skeletal muscle tissue by stimulating
the migration of satellite cells via the modulation of myoblast cell
differentiation, which in turn causes skeletal muscle differentia-
tion (Hawke and Garry, 2001; Bizzarro et al., 2012). In addition,
AnxA1 has a valuable role in inhibiting the negative feedback
effects of glucocorticoids on the release of corticotrophin (ACTH)
and hypothalamic-releasing hormones (Buckingham et al., 2006),
and also affects a number of mediators that are involved in
the inﬂammatory response, including cyclo-oxygenase-2 (Cox-2)
and inducible nitric oxide synthase (iNOS; Minghetti et al., 1999;
Ferlazzo et al., 2003; Perretti and Dalli, 2009).
Evidence indicates that AnxA1 may also play an important
role in tumor development and progression, with AnxA1 levels
being up- and down-regulated in different cancers, e.g., the
loss of AnxA1 expression in prostate cancer correlates with an
early onset of tumorigenesis (Xin et al., 2003). The fact that this
protein also contains phosphorylation sites that can be phospho-
rylated by a number of proliferative signaling molecules, including
PKC and EGF receptor tyrosine kinase, suggests that AnxA1
may also have a role in signaling pathways that are important
in cancer (Alldridge et al., 1999; Hsiang et al., 2006). However,
further work is required to deﬁne the actions of AnxA1 in this
setting.
AnxA1 AND CELL RECRUITMENT AND MIGRATION
AnxA1 has been shown to induce a number of effects relat-
ing to the adhesion and migration of leukocytes, processes that
represent fundamental steps in the development of the inﬂam-
matory response. These include induction of L-selectin shedding
by neutrophils, and detachment of adherent leukocytes from the
endothelium (Figure 1). These actions contribute to the ability
of AnxA1 to restrict leukocyte transmigration and recruitment
during inﬂammation. AnxA1 has also been shown to reduce α4β1
integrin-dependentmonocyte adhesion andmigration (Cote et al.,
2010). This anti-migratory capacity extends to other cell types
such as endothelial cells (Cote et al., 2010). However, in contrast
to its predominantly inhibitory effects on these processes, a recent
study demonstrated that a novel cleavage product from the C ter-
minus of AnxA1, released by activatedneutrophils, acts to promote
neutrophil transmigration by promoting clustering of intracellu-
lar adhesion molecule-1 (ICAM-1) on the endothelial cell surface
around migrating neutrophils (Williams et al., 2010).
EXTERNALIZATION OF AnxA1
In order for AnxA1 to exert its anti-inﬂammatory effects, it must
be externalized by its cellular sources. However, AnxA1 lacks a
signal peptide (similar to other proteins such as interleukin-1;
Muesch et al., 1990; Christmas et al., 1991), and as such, cannot
be exported through the classical secretory pathway, but rather by
exocytosis. Upon cellular activation, AnxA1 is released from its
storage site and translocates to the membrane, where it is secreted
via different pathways, depending upon the cell type involved. In
macrophages, the ATP-binding cassette (ABC) transporter system
is responsible for the secretion of AnxA1 (Wein et al., 2004). In
the neutrophil, AnxA1 is stored in gelatinase granules, and upon
neutrophil-activating events, such as adhesion to the endothe-
lial cell surface, it is rapidly mobilized to the outside leaﬂet of
the plasma membrane (Perretti et al., 1996). In this location, the
intact 37 kDa AnxA1 undergoes conformational change (Rosen-
garth et al., 2001a,b), exposing the N-terminal region, resulting in
a structure which evidence indicates is the active form of AnxA1.
In addition AnxA1 can be cleaved into a 33-kDa fragment. Several
enzymes have been suggested to cause the cleavage, including elas-
tase (Rescher et al., 2006), a metalloprotease (proposed to cleave
the ﬁrst seven amino acids of the AnxA1 terminus; Movitz et al.,
1999), and proteinase 3 (Vong et al., 2008). It is still unknown
whether the cleavage process occurs (1) to allow AnxA1 to act as
a pro-drug via the production of a bioactive fragment, or (2) to
produce homeostasis by limiting the action of AnxA1 (Perretti and
Gavins, 2003; Pederzoli-Ribeil et al., 2010). Supporting the latter
concept, a modiﬁed recombinant form of AnxA1 resistant to pro-
teinase 3-mediated cleavage has been shown to have longer-lasting
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FIGURE 1 | Effects of AnxA1 on leukocyte–endothelial cell interactions.
The effects of AnxA1 on leukocyte endothelial cell interactions include:
(1) induction of L-selectin-shedding, which may reduce leukocyte rolling.
(2) Inhibition of leukocyte adhesion or detachment of already adherent
leukocytes, an effect associated with reduced transmigration. (3) A novel
cleaved form of AnxA1 has been reported to act on endothelial cells to
promote ICAM-1 clustering around transmigrating neutrophils, facilitating
transmigration.
effects on neutrophil adhesion in vivo, relative to native AnxA1
(Pederzoli-Ribeil et al., 2010). In addition, of interest, in the case of
the neutrophil, it has recently been shown that AnxA1 externaliza-
tion can occur without interaction with an endothelial monolayer
indicating that cellular adhesion to the endothelium is not required
for release of AnxA1 (Vong et al., 2008).
Microparticle release may be an additional alternative mode of
AnxA1 release from neutrophils. Microparticles are small vesicles
released from activated cells, and neutrophil-derived micropar-
ticles have been shown to be rich in AnxA1 (Dalli et al., 2008).
Furthermore, neutrophil-derived microparticles have been shown
to inhibit neutrophil–endothelial cell interactions under ﬂow in
vitro, an effect dependent on AnxA1 present in the microparticles.
These observations indicate thatAnxA1-containingmicroparticles
may be a critical source of functionally-relevant AnxA1 produced
by neutrophils.
MECHANISMS OF ACTION OF AnxA1
Until 2000, the way in which AnxA1 mediated its cellular
effects remained unclear. However, a seminal paper by Gerke
and colleagues demonstrated that formyl peptide receptor (FPR)
antagonists [butyloxycarbonyl (Boc) derivatives] blocked the anti-
migratory effects of both intact AnxA1, and the AnxA1-derived
peptide Ac2-26, on human neutrophils, as well as modulating the
effects of AnxA1 on calcium ﬂux and L-selectin shedding (Walther
et al., 2000). These in vitro effects were mirrored in vivo using
Fpr1−/− mice, which displayed an attenuation of the inhibitory
actions of AnxA1 and peptide Ac2-26 in a model of peritoni-
tis (Perretti et al., 2001). Together, these studies were the ﬁrst to
demonstrate a role for FPRs in mediating the cellular effects of
AnxA1.
THE FORMYL PEPTIDE RECEPTORS
Evidence now indicates that AnxA1 mediates most of its cellular
effects via interaction with FPRs (Figure 2). The FPRs are a fam-
ily of seven transmembrane domain, G protein-coupled receptors,
that are expressed mainly in mammalian phagocytic leukocytes,
where they serve to induce responses to various ligands, including
the bacteria-derived peptide, fMLF (Ye et al., 2009). Three FPR
receptors exist in the human, namely FPR1, FPR2/ALXR (which
shares 69% amino acid sequence homology with FPR1, and is also
known as the LXA4 receptor) and FPR3 (which shares 56% amino
acid similarity to FPR1 and 72% to FPR2/ALXR; Brink, 2003; Ye
et al., 2009; Gavins,2010). The receptor story in themouse is rather
more complicated with the gene cluster having undergone differ-
ential expansion. It is now agreed that Fpr1, the murine ortholog
of human FPR1, is 77% identical to human FPR1 (Brink, 2003;
Ye et al., 2009; Gavins, 2010) and Fpr3 is 73% identical to human
FPR2/ALXR. Fpr2 binds fMLF with low afﬁnity (Brink, 2003; Ye
et al., 2009; Gavins, 2010). Fprs3, 4, 6, and 7 appear not to have
direct counterparts in the human genome (Yang et al., 2004; for
further review of these receptors, see Brink, 2003; Ye et al., 2009;
Gavins, 2010).
The FPRs are primarily coupled through pertussis toxin-
insensitive G proteins (GIα2, GIα3) to the activation of phos-
pholipase C and ultimately release Ca2+ from intracellular stores
(Wenzel-Seifert et al., 1999). This release of Ca2+ causes the
opening of the store-operated Ca2+ channel in the plasma mem-
brane allowing further Ca2+ inﬂux into the cell (Ye et al., 2009).
Other intracellular signaling effects of ligand binding to FPRs
include tyrosine kinase-mediated phosphorylation of PLA, PLD,
and members of the MAP kinase family (Brink, 2003; Ye et al.,
2009; Gavins, 2010), and signaling through Cdc42 to activate
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FIGURE 2 | Cellular receptors for AnxA1. AnxA1 is released from
granules of activated neutrophils into the extracellular space, where it is
then able to bind to G protein-coupled receptors including FPR2/ALXR and
FPR1, thereby mediating cellular effects via autocrine (and paracrine)
pathways. In addition, proteases released from activated neutrophils can
cleave full-length AnxA1, although the purpose of this process (for AnxA1
to act as a pro-drug, or whether it is a catabolic event terminating its action)
is still under debate.
Rac- and ARP2/3-dependent pathways leading to actin nucleation
(VanCompernolle et al., 2003).
FPRs AND AnxA1
Upon binding to the FPRs on neutrophils, AnxA1 induces
responses such as L-selectin shedding and detachment from the
endothelium (Perretti et al., 1996; Lim et al., 1998; Gavins et al.,
2003). It has also been shown to cause desensitization of the
receptor toward the fMLF stimulus (D’Acquisto et al., 2008). Evi-
dence indicates that much of the AnxA1 that mediates this effect
comes from the leukocyte itself (D’Acquisto et al., 2008). This
autocrine/paracrine effect of AnxA1, which inhibits the process
of leukocyte transmigration, has been suggested speciﬁcally for
leukocytes (Maderna et al., 2005), but it is likely that it occurs in
a number of different cells, including macrophages (Babbin et al.,
2006) and epithelial cells (Solito et al., 2000).
The speciﬁc member(s) of the FPR family mediating the effect
of AnxA1 and its mimetic peptides appear to be not only tissue-
speciﬁc, but also different depending upon whether full-length
AnxA1 orAnxA1-derived peptide is used (Yang et al., 2004; Gavins
et al., 2005a,b). For example, in a model of peritoneal inﬂamma-
tion induced by zymosan A, the anti-migratory effect of peptide
Ac2-26 was absent in Fpr1 null mice, whereas the response to
whole protein was not (Perretti et al., 2002). In the murine mesen-
tery, both Fpr1 and Fpr2 appear to be involved, with the latter
receptor being more functionally involved in the detachment of
leukocytes from the endothelium (Gavins et al., 2003).
Further evidence of an interaction between AnxA1 and FPRs
came from immunoprecipitation studies in which neutrophil-
derived AnxA1 could be immunoprecipitated with FPR2/ALXR
when the leukocytes were adherent to endothelial monolayers
(Solito et al., 2003). These data were supported by ligand-binding
studies using transfected cells stably expressing members of the
FPR family.
With respect to formylated mitochondria proteins, studies
have reported that mitochondrial-derived FPR1 ligands function
as chemotactic damage-associated molecular pattern molecules
(DAMPs, also known as or alarmins or danger signals; McDonald
et al., 2010; Reddy and Standiford, 2010). DAMPs have pro-
inﬂammatory activity and are released or generated after injury,
thus activating the innate immune system (Chen and Nunez, 2010;
Rock et al., 2010). To our knowledge, no studies have shown an
involvement of AnxA1 in modulating the inﬂammatory response
to injury associated with formylated mitochondria proteins.
It isworthpointing out that LXA4 and its analogs have opposing
effects toAnxA1 and its mimetic peptides, despite both interacting
with FPR2/ALXR on peripheral blood leukocytes. WhereasAnxA1
and its peptides (Walther et al., 2000; Jozsef et al., 2002; Solito et al.,
2003) cause L-selectin shedding by both neutrophils and mono-
cytes in vitro, LXA4 and its analogs increase basal cell surface levels
of L-selectin (Gavins et al., 2005b). These observations may be
due to ligand-speciﬁc conformation that may occur with the same
receptor, resulting in ligand-speciﬁc signal transduction responses
that yield speciﬁc cellular effects unique to each particular ligand
(Gavins et al., 2005a).
AnxA1−/− MOUSE
The development of the AnxA1−/− mouse (generated by homol-
ogous recombination, with a transgenic gene that disrupted the
endogenousAnxA1 gene, and a LacZ gene under the control of the
AnxA1 promoter; Hannon et al., 2003) has led to a greater under-
standing of the roles played by AnxA1 in inﬂammation, and has
demonstrated that, in general, where AnxA1 is absent, inﬂamma-
tion is exacerbated and prolonged. This has important signiﬁcance
in exploiting the biological properties of AnxA1 in development of
novel anti-inﬂammatory agents. AnxA1−/− mice have a height-
ened inﬂammatory response as displayed by increased leukocyte
transmigration (Chatterjee et al., 2005), higher levels of inﬂamma-
tory markers in a model of localized joint inﬂammation (Reddy
and Standiford, 2010), increased neurological deﬁcit in a stroke
model (Gavins et al., 2007) and delayed repair in a model of colitis
(Babbin et al., 2008). In vitro, neutrophils from these mice have
a greater propensity for chemotaxis and higher CD11b expres-
sion. In addition, consistent with these observations, absence of
AnxA1 also leads to increased inﬂammation and in some cases a
higher mortality in life-threatening inﬂammation-associated con-
ditions, e.g., stroke (Reddy and Standiford, 2010). In many of
these inﬂammatory conditions and situations, the administration
of exogenous AnxA1 is able to rescue the phenotype in AnxA1−/−
mice (Gavins et al., 2003).
PRO-INFLAMMATORY ACTIONS OF AnxA1
In contrast to much of the research on AnxA1 and innate
immunity, some studies have pointed to the capacity of this
protein and its cleavage products to mediate pro-inﬂammatory
actions. For example, as described earlier, Williams et al. (2010)
found that that a novel cleavage product of AnxA1 promotes
neutrophil transmigration via effects on endothelial ICAM-1.
Similarly, a peptide from the N-terminal domain of AnxA1 has
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been found to promote leukocyte chemotaxis via FPR family
members (Ernst et al., 2004). AnxA1 has also been found to be
released from rheumatoid arthritis synovial ﬁbroblasts (RASF)
following TNF-mediated activation, and to promote RASF matrix
metalloproteinase-1 secretion (Tagoe et al., 2008). Furthermore,
the absence of AnxA1 has recently been reported to be without
effect in a T cell-independent, antibody transfer model of arthri-
tis, indicating that under some conditions, the role of AnxA1 is
minimal (Patel et al., 2012). These studies demonstrate the mul-
tifaceted nature of the actions of this intriguing molecule and its
cleavage products, and highlight the necessity for detailed studies
in the complex in vivo environment in order to fully understand
their actions in inﬂammatory responses.
AnxA1 AND THE ADAPTIVE IMMUNE RESPONSE
As already described, much of the research on AnxA1 has focused
on its effects in forms of inﬂammation mediated by neutrophils
and monocyte/macrophages. However, a growing body of evi-
dence indicates that AnxA1 also modulates the adaptive immune
response and tissue injury in models of inﬂammation induced
by activation of the adaptive immune system (D’Acquisto et al.,
2008). A notable difference between these sets of observations is
that studies of innate responses routinely report that AnxA1 medi-
ates anti-inﬂammatory effects, while data emerging from studies
on the role of AnxA1 in the adaptive immune response have been
much less consistent. In this section, we will examine these studies
and summarize the evidence regarding the actions of AnxA1 in
the adaptive response.
POSITIONING AnxA1 IN THE DEVELOPMENT OF THE ADAPTIVE
RESPONSE
To understand the potential actions of AnxA1 in adaptive immu-
nity, i.e., responses mediated via antigen recognition by T cells,
B cells, and antibody, it is important to understand the typi-
cal steps in the development of an adaptive immune response.
After emerging from the thymus, naïve T cells migrate to periph-
eral lymphoid organs, where they can undergo activation upon
exposure to cognate antigen presented via dendritic cells. Simi-
larly, immature B cells migrate from the bone marrow into the
periphery and subsequently undergo antigen-dependent activa-
tion promoting their maturation into antibody-secreting cells.
This initial phase is termed the activation or sensitization phase.
As a result of these activation processes, the immune response is
primed to react rapidly to re-exposure to the same antigen. This
antigen-speciﬁc “effector response” commonly occurs in periph-
eral tissues in response to local re-application of the same cognate
antigen, resulting in a long-lived inﬂammatory response at the site
of exposure. Examples of experimental models used to investigate
themechanisms of this process include experimental autoimmune
encephalomyelitis (EAE), antigen-induced arthritis, and dermal
contact hypersensitivity, in which the effector phases target the
brain, joint, and skin, respectively (Liu et al., 1998; Reddy and
Standiford, 2010; Deane et al., 2012). The complexity of these
multi-step processes allows numerous opportunities for AnxA1 to
exert effects.
It is reasonable to assume that forAnxA1 to participate in devel-
opment of the adaptive response, that the key cellular players
would express AnxA1 and/or FPR2/ALXR. As such, it was rec-
ognized many years ago that AnxA1 is expressed constitutively by
T cells, although at ∼25% of the levels expressed in neutrophils
(Goulding et al., 1990; Morand et al., 1995; Perretti and Flower,
1996; Paschalidis et al., 2009; Spurr et al., 2011). In addition, while
unstimulated T cells have been shown to express FPR2/ALXR at
low or negligible levels, following stimulation they increase surface
expression of FPR2/ALXR within 30 min, maintaining elevated
expression for several hours (D’Acquisto et al., 2007a). In addition,
T cells release AnxA1 following activation of the T cell receptor
(TCR; D’Acquisto et al., 2007b). Recent studies have performed
more detailed analyses of the expression of AnxA1, and its recep-
tor, in a range of T cell subsets. This work reveals that CD4+ T cells
express slightly more AnxA1 than CD8+ T cells, predominantly
intracellularly. Further analysis of theCD4+ subsets demonstrated
that activated and memory cells express more AnxA1 than naïve
cells, both intracellularly and on the cell surface. FPR2/ALXR is
also expressed at a higher level in post-activation T cells, although
the scale of increase is smaller relative to that of AnxA1 (Spurr
et al., 2011). B cells also express intermediate levels of AnxA1 but
low levels of FPR2/ALXR in the absence of stimulation (Spurr
et al., 2011). Dendritic cells have also been shown to constitu-
tively express and release AnxA1 (Huggins et al., 2009). Together
these ﬁndings raise the possibility that AnxA1 may have important
actions on these cell types.
AnxA1 AND SUPPRESSION OF THE ADAPTIVE RESPONSE
Early studies of the actions of AnxA1 (“lipomodulin”) provided
evidence that AnxA1 has the capacity to promote the develop-
ment of anti-inﬂammatory regulatory T cells. This effect, detected
using thymocyte-based suppression assays, was complex in that it
occurredundermoderate stimulatory conditions, butwas reversed
in response to strong T cell stimulation via high concentration
Con A (Hirata and Iwata, 1983). Nevertheless, this study was
interpreted to indicate that at least under some activating con-
ditions, AnxaA1 promotes the generation and/or maturation of
“suppressor” T cells. These ﬁndings were consistent with AnxA1
acting to limit T cell-dependent responses under some condi-
tions. Parallel ﬁndings were reported by Gold et al. (1996), who
observed suppression of T cell proliferation in response to exoge-
nous AnxA1, using antigen-stimulated rat T cell lines. Similarly,
proliferation and activation of peripheral blood mononuclear
cells (PBMC) from atopic individuals were found to be inhib-
ited in the presence of exogenous AnxA1-derived peptides, Ac2-26
and antiﬂammin-2 (AF-2; aa246–254; Figure 3; Kamal et al.,
2001). The use of PBMC in this study made it unclear which
leukocyte subsets were involved in the response. However, these
cells were stimulated with peptide antigens known to induce T
cell responses in the donors (house dust mite allergen – Der
p; puriﬁed protein derivative of Mycobacterium tuberculosis –
PPD), ensuring that stimulation occurred in an antigen-speciﬁc,
T cell-dependent manner. While this did not exclude actions of
AnxA1 in other leukocyte subsets present in the PBMC prepa-
ration, it ensured that the T cell was the primary target of the
activation.
This work was extended into the in vivo setting by Yang et al.,
who examined AnxA1−/− mice in an antigen-induced model of
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FIGURE 3 | Peptide structure of AnxA1. Schematic representation of AnxA1 and peptides derived from the primary sequence.
arthritis mediated by initial sensitization to mBSA, and subse-
quent local intra-articularmBSAchallenge (Reddy andStandiford,
2010). In this study, absence of AnxA1 was associated with
increased joint inﬂammation, consistent with AnxA1 acting to
limit this adaptive response. Interestingly, in parallel with this
result, antigen-speciﬁc IgG levels were reduced in AnxA1−/−
mice, despite the exacerbation of inﬂammation. This ﬁnding
raises the intriguing possibility that under some circumstances,
AnxA1 has the opposing effect on B cell function and generation of
humoral immunity as it does on T cell-dependent inﬂammation.
More recently, the role of AnxA1 was examined in an ovalbu-
min (OVA)-induced model of airways hyperresponsiveness (Ng
et al., 2011). Similar to the arthritis study, the absence of AnxA1
was associated with evidence of increased allergic inﬂammation in
the OVA-challenged lung, including increased eosinophil recruit-
ment, IL-4 production, and airways dysfunction. However, this
study revealed unanticipated complexities in the actions of AnxA1.
Firstly, despite the exacerbation of inﬂammation in AnxA1−/−
mice, antigen-induced activation of MAP kinase and NFκB path-
ways in lungs of these animals were markedly blunted relative
to that in wild-type mice. Furthermore, the absence of AnxA1
was associated with exacerbated airway reactivity in naïve mice,
i.e., mice those had not undergone sensitization to antigen. These
ﬁndings pointed to unidentiﬁed actions of AnxA1 in pulmonary
physiology, presumably unrelated to its actions in the immune
system.
Together these studies provide evidence that AnxA1 acts to
limit inﬂammation in models associated with activation of the
adaptive immune system. However, the molecular mechanisms of
these effects, and the range of cellular targets of AnxA1, remain
to be fully characterized. Furthermore, as these experiments pre-
dominantly focused on whole animal approaches, they did not
determine whetherAnxA1 mediated these effects directly in T cells
or other cells involved in development of the adaptive response.
Given the broad range of actions of AnxA1, it is conceivable that
the absence of AnxA1 from cells in the target tissue with key roles
in the effector response, potentially including endothelial cells or
other effector leukocyte populations such as neutrophils,may have
contributed to the exacerbation of inﬂammation in the absence
of AnxA1. This is particularly important in the context of an
unexpected association between exacerbated inﬂammation and
defective T cell activation.
AnxA1 AND ACTIVATION OF THE Th1 RESPONSE
In contrast to the work described above, a further group of studies
has provided evidence thatAnxA1promotesT cell activation andT
cell-dependent inﬂammation. In initial studies, D’Acquisto et al.
(2007b) examined the effects of recombinant AnxA1 on T cells
undergoing anti-CD3/CD28 activation, observing increased pro-
liferation and IL-2 production in response to AnxA1. The effect of
AnxA1 was most evident in T cells undergoing sub-maximal stim-
ulation, while AnxA1 alone was insufﬁcient to activate T cells. This
effect was associated with increased TCR-dependent signaling, as
demonstrated by activation of AP-1, NFκB, and NFAT. T cell acti-
vation also rapidly increased surface expression of FPR2/ALXR
and exteriorization and release of AnxA1, and increased phos-
phorylation of ERK and Akt, signaling pathways downstream of
FPR2/ALXR.
Numerous studies have demonstrated that following activation,
CD4+ T cells differentiate downdistinct lineages (Th1, Th2, Th17)
deﬁned by the proﬁle of the cytokines they produce. Moreover,
in vivo the composition of these subsets determines the pheno-
type of the resultant effector response (Iwakura et al., 2008; Zhu
and Paul, 2010). D’Acquisto et al. (2007b) investigated the effect
of AnxA1 on T cell differentiation and observed that exogenous
AnxA1 favored generation of the IFNγ-producing Th1 subset,
while inhibiting development of the IL-4-producing Th2 subset.
To test if this subset“skewing”also occurred in vivo, they examined
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the Th1-dominant collagen-induced model of arthritis (CIA) and
observed that exogenously administeredAnxA1 induced exacerba-
tion of joint inﬂammation associated with increased lymphocyte
production of the key Th1 cytokine, IFN-γ. In this experiment,
recombinant AnxA1 was administered twice daily commencing
immediately after immunization. The presence of exogenous
AnxA1 at these early stages of immunization in parallel with the
signiﬁcant enhancement of disease severity suggests that T cell dif-
ferentiationwas an important target of AnxA1 in thismodel. These
ﬁndings support the hypothesis thatAnxA1 alone does not directly
activate T cells, but enhances activation and Th1 differentiation in
the context of conventional T cell activation.
In complementary studies, the same group examined responses
of T cells fromAnxA1−/− mice (D’Acquisto et al., 2007a). Notably,
AnxA1−/− T cells were found to undergo a signiﬁcantly higher
rate of basal proliferation relative to wild-type T cells. However,
following non-speciﬁc activation, AnxA1−/− T cells displayed
signiﬁcant reductions in proliferation and cytokine production
relative to comparably-activated wild-type cells (D’Acquisto et al.,
2007b). These ﬁndings indicate that the actions of AnxA1 dif-
fer according to the state of T cell activation. Consistent with
previous work, in activated cells the absence of AnxA1 was asso-
ciated with reduced activation of signaling pathways downstream
of the TCR and Fpr2/ALXR (AP-1, NFκB, NFAT, MAP kinase,
Akt; Ng et al., 2011). Mirroring the effect of exogenous AnxA1 on
Th1 development, the absence of AnxA1 favored development of
IL-4/IL-13-generatingTh2 cells (D’Acquisto et al., 2007b). In addi-
tion,AnxA1−/− Tcells produced less IL-17, suggesting thatAnxA1
also supports development of the Th17 CD4+ T cell phenotype.
Data from a Th2-dependent model of allergic peritonitis sup-
ported this idea in that AnxA1−/− mice showed increased effector
phase leukocyte recruitment, most prominently of eosinophils.
These studies provide evidence that the actions of AnxA1 on T
cell activation are subset-speciﬁc, promoting development of the
Th1 and Th17 subsets, while inhibiting development of the Th2
response.
This work was extended to the examination of T cell-mediated
inﬂammation of the central nervous system (Paschalidis et al.,
2009). Using the myelin oligodendrocyte glycoprotein (MOG)-
induced model of EAE, Paschalidis et al. (2009) observed a mild
protection from clinical disease in AnxA1−/− mice, most promi-
nently in the later phase of the disease. This was associated with
reduced antigen-speciﬁc recall proliferation and IL-2 production,
and reduced T cell production of Th1 and Th17 cytokines in
AnxA1−/− mice.
Together this body of work indicates that endogenous AnxA1
acts to restrict Th2 development, favoring development of Th1-
and Th17-mediated responses. These ﬁndings raise the possibil-
ity of AnxA1 being a therapeutic target in autoimmune diseases
characterized by inappropriate activity of Th1/Th17 subsets.
AnxA1 AND THE ADAPTIVE RESPONSE – WHERE TO FROM HERE?
Taken together, some inconsistencies between these studies
remain, indicating that further work is required to clarify the
actions of AnxA1 in T cell-mediated responses. One of the
fundamental questions that emerges is, via what mechanism does
AnxA1 promote Th1/Th17 development while inhibiting Th2
development? To this end, there is a growing body of evidence
that control of T cell activation via modulation of T cell signaling
is a key component of this action of AnxA1. In T cells exposed
to a range of stimuli, AnxA1 has been found to modulate acti-
vation of Akt and ERK MAP kinase, pathways that are central to
the TCR-mediated response (D’Acquisto et al., 2007a,b; Pascha-
lidis et al., 2009). Further work is required to determine how these
intracellular effects control the polarization of CD4+ T cells dur-
ing development of the immune response. An additional aspect
that remains unclear is what are the actions of AnxA1 in differ-
ent cell types? In none of the in vivo studies described has the
absence of AnxA1 been restricted to T cells. As such, it is not
possible to attribute changes in the resultant in vivo response to
effects of AnxA1 speciﬁcally in T cells. Studies of this nature are
critical in that it is beyond doubt that the actions of AnxA1 extend
well beyond T cell activation. As already described, numerous
studies have demonstrated that AnxA1 acts to restrict recruit-
ment of innate leukocyte subsets, targeting key events in the
microvasculature. These leukocytes are critical “responder cells”
in the development of T cell-mediated inﬂammation. Therefore,
in addition to its effects on T cell activation, inhibition or absence
of AnxA1 in vivo has the potential to dramatically modulate the
effector response in the periphery. In addition, while early stud-
ies provided evidence of an effect of AnxA1 on regulatory T cell
function (Hirata and Iwata, 1983), this concept remains to be fully
explored. Similarly, unanticipated actions of AnxA1, possibly in
non-immune cells, as exempliﬁed by the observation of altered
basal lung function in AnxA1−/− mice (Ng et al., 2011) require
further investigation. These complexities will be best addressed
in studies in which AnxA1 deﬁciency is restricted to antigen-
speciﬁc T cells, regulatory T cells, dendritic cells, or non-immune
cells.
EFFECT OF EXOGENOUS AnxA1 AND AnxA1-DERIVED
PEPTIDES
Much of the interest in AnxA1 as a potential therapeutic has
stemmed fromresults of its use as an exogenous anti-inﬂammatory
agent in in vivo models of inﬂammation. For example, human
recombinant AnxA1 has been shown to exert anti-inﬂammatory
effects in a carrageenan-induced edema model of inﬂammation in
the rat paw (Wu et al., 1995). However, a great deal of this work
has examined the effects of peptides derived from AnxA1. From
a protein of over 300 amino acids, several small peptides derived
from the N-terminal region of AnxA1 retain much of its biolog-
ical activity. These peptides, termed Ac2-26, Ac2-12, or Ac9-25
(constructed with an acetyl-blocked N-terminus for stability and
delay of proteolytic degradation) have all been reported to retain
the majority of the effects of the full-length AnxA1 protein in a
number of different in vitro and in vivo systems.
The anti-inﬂammatory effects of peptide Ac2-26 have been
demonstrated innumerousmodels including ischemia/reperfusion
injury in both the rat (D’Amico et al., 2000; La et al., 2001)
and mouse (Gavins et al., 2003), the mouse air-pouch and rat
paw edema models of inﬂammation (Cirino et al., 1993; Per-
retti et al., 1993), and in models of neutrophil and monocyte
trafﬁcking (Szabó et al., 1997; Bandeira-Melo et al., 2005). The
wide-ranging effects of peptide Ac2-26 were clearly demonstrated
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in a model of pleurisy in the rat, in which the peptide inhibited
mast cell degranulation, plasma protein leakage, and accu-
mulation of both neutrophils and eosinophils (Teixeira et al.,
1998). It is important to note that the evidence is consistent
with peptide Ac2-26 mediating these anti-inﬂammatory effects
by impacting on several distinct mechanisms. For example, in
ischemia/reperfusion of the heart, AnxA1 modulated inﬂamma-
tion via effects on blood-borne cells (La et al., 2001; Gavins et al.,
2005a), as well as by having direct effects on cardiomyocytes
(Ritchie et al., 2003).
One of the most important techniques employed in teas-
ing out the effects of pharmacological doses of AnxA1 and its
mimetic peptides on the inﬂammatory cascade has been intrav-
ital microscopy (IVM). Directly imaging the microvasculature
during an inﬂammatory response has been critical in demon-
strating the ability of exogenously administered AnxA1 to reduce
the capacity of leukocytes to adhere to and migrate through
inﬂamed post-capillary venules (Lim et al., 1998; Gavins et al.,
2003). Exogenous administration of AnxA1 to mice following
clamping and release of the superior mesenteric artery to induce
ischemia/reperfusion injury, resulted in an anti-inﬂammatory
effect that was associated with the detachment of neutrophils from
the endothelium (Gavins et al., 2003). This demonstration of an
effect of AnxA1 on leukocyte recruitment is further supported
by in vitro studies, which demonstrate that AnxA1 inhibits ﬁrm
adhesion of neutrophils to human umbilical vein endothelial cells
under ﬂow conditions. However in contrast, the AnxA1-derived
peptide, Ac2-26, only reduces leukocyte capture and rolling
without affecting ﬁrm adhesion (Hayhoe et al., 2006) or alter-
ing increased vascular permeability (Cirino et al., 1989; Gavins
et al., 2003). These ﬁndings provide evidence that the actions of
peptide Ac2-26 do not entirely overlap with those of full-length
AnxA1.
The examination of the therapeutic efﬁcacy of AnxA1 has
recently been extended to an OVA-induced model of antigen-
induced airways inﬂammation (Perretti et al., 1993) This study
examined the effect of a cell-permeable form of AnxA1, admin-
istered as an exogenous anti-inﬂammatory agent to wild-type
mice during the sensitization phase of the model (Lee et al.,
2012). Administration of AnxA1 conjugated to a “Tat” cell-
penetrating peptide, during the latter stages of OVA sensitization,
alleviated inﬂammation, cytokine production, airways hyper-
responsiveness, and OVA-speciﬁc IgE production. Notably, while
the Tat-conjugated form of AnxA1 was therapeutically effective,
native AnxA1 administered in a similar fashion did not signiﬁ-
cantly reduce disease parameters. This ﬁnding suggests that the
capacity of Tat-AnxA1 to enter target cells was critical in achieving
its anti-inﬂammatory effect in this setting.
IMPACT OF AnxA1 IN DRUG DISCOVERY
The identiﬁcation of the mechanism of actions of AnxA1
(notwithstanding the unresolved question of whether the role
of FPR2/ALXR is pro-inﬂammatory or anti-inﬂammatory; Per-
retti and Dalli, 2009), in parallel with the attractive concept of
developing novel therapeutic agents based on mimicking speciﬁc
endogenous pathways, has lead to an increase in drug discov-
ery programs within this area. The ultimate aim of treatments
based on AnxA1 is to retain the anti-inﬂammatory properties
of glucocorticoids that signal for the resolution of inﬂammatory
events, while avoiding the highly detrimental potential metabolic
side effects of long-termuse of exogenous glucocorticoids (Perretti
and Gavins, 2003).
One strategy for this would be to identify new chemical entities
from biologically-active peptide sequences from the N-terminus
of AnxA1. However, from a drug discovery point of view, small
molecules are a more attractive proposition due to their more
attractive pharmacokinetic properties. Thus, the identiﬁcation of
the receptor by which AnxA1 mediates its biological effects (i.e.,
via FPR2/ALXR) has stimulated a great deal of interest. For exam-
ple, Amgen have developed a program to identify small chemical
entities that are speciﬁc for FPR2/ALXR (Perretti and Dalli, 2009).
In addition, novel computer modeling approaches are now being
used to identify ligands that are speciﬁc for members of the FPR
family, in several cases for FPR2/ALXR (Shemesh et al., 2008;
Hecht et al., 2009). The ultimate aim of this work is to identify a
lowmolecular weight compoundwith the capacity to interact with
FPR2/ALXR tomediate a comparable proﬁle of anti-inﬂammatory
effects to that of AnxA1
CONCLUSION
Inﬂammatory disease affects a huge number of patients world-
wide. In many cases, the therapeutic approaches in use for these
patients have not changed for the last 30 years. Treatments such as
exogenous glucocorticoids remain a ﬁrst-line therapy for preva-
lent diseases such as rheumatoid arthritis. Indeed their efﬁcacy
in inhibiting inﬂammation ensures they remain a favored thera-
peutic modality, despite their well-established highly detrimental
metabolic side effects. The next level of sophistication however, is
to investigate the mechanisms of action of glucocorticoids in these
patients, and to learn more about the endogenous pathways glu-
cocorticoids mobilize and interact with to inhibit inﬂammation.
AnxA1 is a prime example of this approach. The investigation
of the mechanisms of action of AnxA1, as well as those of
its breakdown products and receptors, holds great promise for
the development of more speciﬁc novel therapies which mimic
the anti-inﬂammatory effects of glucocorticoids, while poten-
tially avoiding the negative effects of glucocorticoid use. AnxA1
has consistently been found to play an inhibitory role in innate
forms of inappropriate inﬂammation. Therefore novel AnxA1-
derived therapeutics are more likely to be immediately applicable
in conditions such as ischemia/reperfusion injury, where the
innate immune system plays a leading role. In contrast, given
the previously-described inconsistency in the reported actions of
AnxA1 in T cell-mediated immunity, this remains premature for
forms of inﬂammation mediated by the adaptive immune system.
However, given more detailed research in this area,AnxA1-derived
therapeutics may also eventually ﬁnd use in speciﬁc forms of T
cell-mediated disease.
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